Loading...

FITC anti-mouse CD69 Antibody FITC anti-mouse CD69 Antibody

Pricing & Availability
Clone
H1.2F3 (See other available formats)
Regulatory Status
RUO
Other Names
Very Early Activation Antigen (VEA), AIM, EA1, MLR3, gp34/28
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
h1.2f3
PMA-stimulated (6 hours) splenocytes stained with H1.2F3 FITC
  • h1.2f3
    PMA-stimulated (6 hours) splenocytes stained with H1.2F3 FITC
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
104506 500 µg NOK2418
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104505 50 µg NOK685
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD69 is a 60 kD type II membrane protein composed of a 27/33 kD disulfide-linked homodimer, also known as Very Early Activation Antigen (VEA), AIM, EA1, MLR3, and gp34/28. It is expressed on a subset of thymocytes and platelets. CD69 is rapidly induced on activated T and B cells, neutrophils, and NK cells. It is a C-type lectin, closely related to the NKR-P1 and Ly-49 NK cell activation molecules. CD69 is involved in the early events of cell activation and thymocyte positive selection.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
Mouse dendritic epidermal T cell line Y245
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The H1.2F3 antibody has been reported to augment T cell activation. Additional reported applications (for the relevant formats) include: in vitro T cell and NK cell activation1-3, immunohistochemistry4,5, and immunoprecipitation1.

This antibody has been characterized in the literature as containing a lambda light chain.

Application References
  1. Yokoyama WM, et al. 1988. J. Immunol. 141:369. (IP)
  2. Sobel ES, et al. 1993. J. Immunol. 150:673.
  3. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  4. Zhou X, et al. 2005. J. Biol. Chem. 280:31240. (IHC)
  5. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC)
  6. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  7. Lee JW, et al. 2006. Nature Immunol. 8:181.
  8. Epardaud M, et al. 2008. Cancer Res. 15:2972. PubMed
  9. Jordan JM, et al. 2008. 76:3717. PubMed
  10. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  11. Ishikawa C, et al. 2013. Biochim Biophys Acta. 167:99. PubMed
Product Citations
  1. Behr FM, et al. 2021. Eur J Immunol. 51:151. PubMed
  2. Jebbawi F, et al. 2021. Parasite Immunol. 43:e12834. PubMed
  3. Parga-Vidal L, et al. 2022. Eur J Immunol. 52:1095. PubMed
  4. Yang J, et al. 2022. Mol Ther Nucleic Acids. 30:184. PubMed
  5. Yu Z, et al. 2022. Biomater Sci. 11:263. PubMed
  6. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  7. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  8. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  9. Ivasko SM, et al. 2023. Front Immunol. 13:1023206. PubMed
  10. Elliot TAE, et al. 2022. Discov Immunol. 1:kyac009. PubMed
  11. Gon Y, et al. 2023. PLoS One. 18:e0279389. PubMed
  12. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  13. Zheng X, et al. 2019. PLoS Pathog. 15:e1008036. PubMed
  14. He Y, et al. 2023. Biomolecules. 13:. PubMed
  15. Song Y, et al. 2020. Front Immunol. 11:558143. PubMed
  16. van Vloten JP, et al. 2022. J Immunother Cancer. 10:. PubMed
  17. Cordero-Reyes A, et al. 2016. J Am Heart Assoc. 5: 002484. PubMed
  18. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  19. Buxadé M, et al. 2018. J Exp Med. 215:2901. PubMed
  20. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  21. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  22. Castellanos CA, et al. 2021. Sci Immunol. 6:eabh0707. PubMed
  23. Liu Q, et al. 2021. Cell Death Dis. 12:240. PubMed
  24. de Mingo Pulido , et al. 2021. Immunity. 54(6):1154-1167.e7. PubMed
  25. Byun JK, et al. 2020. Molecular Cell. 80(4):592-606.e8. PubMed
  26. Burrack AL, et al. 2019. Cell Rep. 28:2140. PubMed
  27. Chen J et al. 2018. Cell reports. 25(12):3393-3404 . PubMed
  28. Álvaro de Mingo Pulido et al. 2018. Cancer cell. 33(1):60-74 . PubMed
  29. Hasezaki T, et al. 2020. Sci Rep. 10:6969. PubMed
  30. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  31. Luff DH, et al. 2021. Front Immunol. 631271:12. PubMed
  32. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  33. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  34. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  35. Bhattacharjee P, et al. 2018. Sci Rep. 13:e0199785. PubMed
  36. Pereira JL, et al. 2021. Transl Oncol. 14:101125. PubMed
  37. Zirngibl F, et al. 2021. J Immunother Cancer. 9:. PubMed
  38. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  39. Park D, et al. 2020. Cancer Res. 80:4172. PubMed
  40. Mandrup OA, et al. 2021. Commun Biol. 310:4. PubMed
  41. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  42. Brummer G, et al. 2020. Oncogene. 39:2275. PubMed
  43. Leonard JD et al. 2017. Immunity. 47(1):107-117 . PubMed
  44. Uhde A, et al. 2016. PLoS One. 11: 0161883. PubMed
  45. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  46. Baier FA, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:745. PubMed
  47. Fontinha D, et al. 2015. PLoS One. 10: 0142540. PubMed
  48. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  49. Stanford S, et al. 2012. Proc Natl Acad Sci U S A. 109:13972. PubMed
  50. Haile S, et al. 2014. Cancer Immunol Res. 2:610. PubMed
  51. White C, et al. 2015. J Immunol. 194:697. PubMed
  52. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  53. Li C, et al. 2020. Immunity. 52(1):201-202. PubMed
  54. Kang X, et al. 2022. J Immunol Res. 2022:8118577. PubMed
  55. Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed
  56. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  57. Lim S, et al. 2016. PLoS One. 11: 0155689. PubMed
  58. XS R, et al. 2015. Diabetes. 64 90. PubMed
  59. Moore MJ et al. 2018. eLife. 7 pii: e33057. PubMed
  60. Ma K, et al. 2022. iScience. 25:104347. PubMed
  61. Tao F, et al. 2013. Biochem Pharmacol. 85:798. PubMed
  62. Zhang W, et al. 2019. Mar Drugs. 0.845138889. PubMed
  63. Kretschmer L, et al. 2020. Nat Commun. 0.536805556. PubMed
  64. Riva A, et al. 2017. PLoS One.. 10.1371/journal.pone.0181964. PubMed
  65. Wang L, et al. 2021. Sci Adv. 7:eabj4796. PubMed
  66. Jing Y, et al. 2021. Front Immunol. 12:651860. PubMed
  67. Martina M, et al. 2016. J Am Soc Nephrol. 27: 1113-1123. PubMed
  68. Kiss M, et al. 2020. Cancer Immunol Res. 9:309. PubMed
  69. Niven J, et al. 2019. Cell Rep. 28:21. PubMed
  70. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  71. Rui J, et al. 2021. Nat Commun. 12:5074. PubMed
  72. Song TY, et al. 2021. Nat Commun. 12:7003. PubMed
  73. Bommareddy PK, et al. 2019. J Biol Methods. 6:2. PubMed
  74. Skirecki T, et al. 2020. JCI Insight. 5:. PubMed
  75. Klezovich-Bénard M, et al. 2012. PLoS One. 8:e1002481. PubMed
  76. Gardner A, et al. 2022. J Immunother Cancer. 10:. PubMed
  77. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  78. Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed
  79. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
  80. Han J, et al. 2015. Cancer Res . 75: 5273 - 5282. PubMed
  81. Kuhn NF et al. 2019. Cancer cell. 35(3):473-488 . PubMed
  82. Behr FM, et al. 2021. Eur J Immunol. 51:151. PubMed
  83. Jebbawi F, et al. 2021. Parasite Immunol. 43:e12834. PubMed
  84. Parga-Vidal L, et al. 2022. Eur J Immunol. 52:1095. PubMed
  85. Yang J, et al. 2022. Mol Ther Nucleic Acids. 30:184. PubMed
  86. Yu Z, et al. 2022. Biomater Sci. 11:263. PubMed
  87. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  88. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  89. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  90. Ivasko SM, et al. 2023. Front Immunol. 13:1023206. PubMed
  91. Elliot TAE, et al. 2022. Discov Immunol. 1:kyac009. PubMed
  92. Gon Y, et al. 2023. PLoS One. 18:e0279389. PubMed
  93. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  94. Zheng X, et al. 2019. PLoS Pathog. 15:e1008036. PubMed
  95. He Y, et al. 2023. Biomolecules. 13:. PubMed
  96. Song Y, et al. 2020. Front Immunol. 11:558143. PubMed
  97. van Vloten JP, et al. 2022. J Immunother Cancer. 10:. PubMed
  98. Cordero-Reyes A, et al. 2016. J Am Heart Assoc. 5: 002484. PubMed
  99. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  100. Buxadé M, et al. 2018. J Exp Med. 215:2901. PubMed
  101. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  102. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  103. Castellanos CA, et al. 2021. Sci Immunol. 6:eabh0707. PubMed
  104. Liu Q, et al. 2021. Cell Death Dis. 12:240. PubMed
  105. de Mingo Pulido , et al. 2021. Immunity. 54(6):1154-1167.e7. PubMed
  106. Byun JK, et al. 2020. Molecular Cell. 80(4):592-606.e8. PubMed
  107. Burrack AL, et al. 2019. Cell Rep. 28:2140. PubMed
  108. Chen J et al. 2018. Cell reports. 25(12):3393-3404 . PubMed
  109. Álvaro de Mingo Pulido et al. 2018. Cancer cell. 33(1):60-74 . PubMed
  110. Hasezaki T, et al. 2020. Sci Rep. 10:6969. PubMed
  111. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  112. Luff DH, et al. 2021. Front Immunol. 631271:12. PubMed
  113. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  114. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  115. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  116. Bhattacharjee P, et al. 2018. Sci Rep. 13:e0199785. PubMed
  117. Pereira JL, et al. 2021. Transl Oncol. 14:101125. PubMed
  118. Zirngibl F, et al. 2021. J Immunother Cancer. 9:. PubMed
  119. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  120. Park D, et al. 2020. Cancer Res. 80:4172. PubMed
  121. Mandrup OA, et al. 2021. Commun Biol. 310:4. PubMed
  122. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  123. Brummer G, et al. 2020. Oncogene. 39:2275. PubMed
  124. Leonard JD et al. 2017. Immunity. 47(1):107-117 . PubMed
  125. Uhde A, et al. 2016. PLoS One. 11: 0161883. PubMed
  126. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  127. Baier FA, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:745. PubMed
  128. Fontinha D, et al. 2015. PLoS One. 10: 0142540. PubMed
  129. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  130. Stanford S, et al. 2012. Proc Natl Acad Sci U S A. 109:13972. PubMed
  131. Haile S, et al. 2014. Cancer Immunol Res. 2:610. PubMed
  132. White C, et al. 2015. J Immunol. 194:697. PubMed
  133. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  134. Li C, et al. 2020. Immunity. 52(1):201-202. PubMed
  135. Kang X, et al. 2022. J Immunol Res. 2022:8118577. PubMed
  136. Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed
  137. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  138. Lim S, et al. 2016. PLoS One. 11: 0155689. PubMed
  139. XS R, et al. 2015. Diabetes. 64 90. PubMed
  140. Moore MJ et al. 2018. eLife. 7 pii: e33057. PubMed
  141. Ma K, et al. 2022. iScience. 25:104347. PubMed
  142. Tao F, et al. 2013. Biochem Pharmacol. 85:798. PubMed
  143. Zhang W, et al. 2019. Mar Drugs. 0.845138889. PubMed
  144. Kretschmer L, et al. 2020. Nat Commun. 0.536805556. PubMed
  145. Riva A, et al. 2017. PLoS One.. 10.1371/journal.pone.0181964. PubMed
  146. Wang L, et al. 2021. Sci Adv. 7:eabj4796. PubMed
  147. Jing Y, et al. 2021. Front Immunol. 12:651860. PubMed
  148. Martina M, et al. 2016. J Am Soc Nephrol. 27: 1113-1123. PubMed
  149. Kiss M, et al. 2020. Cancer Immunol Res. 9:309. PubMed
  150. Niven J, et al. 2019. Cell Rep. 28:21. PubMed
  151. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  152. Rui J, et al. 2021. Nat Commun. 12:5074. PubMed
  153. Song TY, et al. 2021. Nat Commun. 12:7003. PubMed
  154. Bommareddy PK, et al. 2019. J Biol Methods. 6:2. PubMed
  155. Skirecki T, et al. 2020. JCI Insight. 5:. PubMed
  156. Klezovich-Bénard M, et al. 2012. PLoS One. 8:e1002481. PubMed
  157. Gardner A, et al. 2022. J Immunother Cancer. 10:. PubMed
  158. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  159. Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed
  160. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
  161. Han J, et al. 2015. Cancer Res . 75: 5273 - 5282. PubMed
  162. Kuhn NF et al. 2019. Cancer cell. 35(3):473-488 . PubMed
RRID
AB_313109 (BioLegend Cat. No. 104506)
AB_313108 (BioLegend Cat. No. 104505)

Antigen Details

Structure
C-type lectin, 27/33 kD
Distribution

Activated T cells and B cells, NK cells, granulocytes, thymocytes, platelets

Function
Lymphocyte activation
Cell Type
B cells, Granulocytes, NK cells, Platelets, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Testi R, et al. 1994. Immunol. Today 15:479.
3. Moretta A, et al. 1991. J. Exp. Med. 174:1393.
4. Yokoyama WM, et al. 1988. J. Immunol. 141:369.

Gene ID
12515 View all products for this Gene ID
UniProt
View information about CD69 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD69 Reagents Request Custom Conjugation
Description Clone Applications
Purified anti-mouse CD69 (Maxpar® Ready) H1.2F3 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD69 H1.2F3 FC
Brilliant Violet 711™ anti-mouse CD69 H1.2F3 FC
Alexa Fluor® 700 anti-mouse CD69 H1.2F3 FC
Brilliant Violet 650™ anti-mouse CD69 H1.2F3 FC
Brilliant Violet 785™ anti-mouse CD69 H1.2F3 FC
TotalSeq™-A0197 anti-mouse CD69 H1.2F3 PG
APC/Fire™ 750 anti-mouse CD69 H1.2F3 FC
TotalSeq™-C0197 anti-mouse CD69 H1.2F3 PG
TotalSeq™-B0197 anti-mouse CD69 H1.2F3 PG
KIRAVIA Blue 520™ anti-mouse CD69 H1.2F3 FC
Spark NIR™ 685 anti-mouse CD69 H1.2F3 FC
Biotin anti-mouse CD69 H1.2F3 FC
FITC anti-mouse CD69 H1.2F3 FC
PE anti-mouse CD69 H1.2F3 FC
PE/Cyanine5 anti-mouse CD69 H1.2F3 FC
Purified anti-mouse CD69 H1.2F3 FC,IHC-F,IP
PE/Cyanine7 anti-mouse CD69 H1.2F3 FC
APC anti-mouse CD69 H1.2F3 FC
Alexa Fluor® 488 anti-mouse CD69 H1.2F3 FC
Alexa Fluor® 647 anti-mouse CD69 H1.2F3 FC
PerCP anti-mouse CD69 H1.2F3 FC
PerCP/Cyanine5.5 anti-mouse CD69 H1.2F3 FC
Pacific Blue™ anti-mouse CD69 H1.2F3 FC
Brilliant Violet 421™ anti-mouse CD69 H1.2F3 FC
APC/Cyanine7 anti-mouse CD69 H1.2F3 FC
Brilliant Violet 605™ anti-mouse CD69 H1.2F3 FC
Brilliant Violet 510™ anti-mouse CD69 H1.2F3 FC
Spark Red™ 718 anti-mouse CD69 H1.2F3 FC
Spark Blue™ 574 anti-mouse CD69 (Flexi-Fluor™) H1.2F3 FC
Spark PLUS B550™ anti-mouse CD69 H1.2F3 FC
Spark PLUS UV395™ anti-mouse CD69 Antibody H1.2F3 FC
Spark YG™ 581 anti-mouse CD69 (Flexi-Fluor™) H1.2F3 FC
Spark YG™ 593 anti-mouse CD69 (Flexi-Fluor™) Antibody H1.2F3 FC
Spark UV™ 387 anti-mouse CD69 (Flexi-Fluor™) H1.2F3 FC
Go To Top Version: 3    Revision Date: 04.18.2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
H1.2F3 (See other available formats)
Regulatory Status
RUO
Other Names
Very Early Activation Antigen (VEA), AIM, EA1, MLR3, gp34/28
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
h1.2f3
PMA-stimulated (6 hours) splenocytes stained with H1.2F3 FITC
  • h1.2f3
    PMA-stimulated (6 hours) splenocytes stained with H1.2F3 FITC
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
104506 500 µg NOK2418
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104505 50 µg NOK685
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD69 is a 60 kD type II membrane protein composed of a 27/33 kD disulfide-linked homodimer, also known as Very Early Activation Antigen (VEA), AIM, EA1, MLR3, and gp34/28. It is expressed on a subset of thymocytes and platelets. CD69 is rapidly induced on activated T and B cells, neutrophils, and NK cells. It is a C-type lectin, closely related to the NKR-P1 and Ly-49 NK cell activation molecules. CD69 is involved in the early events of cell activation and thymocyte positive selection.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
Mouse dendritic epidermal T cell line Y245
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The H1.2F3 antibody has been reported to augment T cell activation. Additional reported applications (for the relevant formats) include: in vitro T cell and NK cell activation1-3, immunohistochemistry4,5, and immunoprecipitation1.

This antibody has been characterized in the literature as containing a lambda light chain.

Application References
  1. Yokoyama WM, et al. 1988. J. Immunol. 141:369. (IP)
  2. Sobel ES, et al. 1993. J. Immunol. 150:673.
  3. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  4. Zhou X, et al. 2005. J. Biol. Chem. 280:31240. (IHC)
  5. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC)
  6. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  7. Lee JW, et al. 2006. Nature Immunol. 8:181.
  8. Epardaud M, et al. 2008. Cancer Res. 15:2972. PubMed
  9. Jordan JM, et al. 2008. 76:3717. PubMed
  10. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  11. Ishikawa C, et al. 2013. Biochim Biophys Acta. 167:99. PubMed
Product Citations
  1. Behr FM, et al. 2021. Eur J Immunol. 51:151. PubMed
  2. Jebbawi F, et al. 2021. Parasite Immunol. 43:e12834. PubMed
  3. Parga-Vidal L, et al. 2022. Eur J Immunol. 52:1095. PubMed
  4. Yang J, et al. 2022. Mol Ther Nucleic Acids. 30:184. PubMed
  5. Yu Z, et al. 2022. Biomater Sci. 11:263. PubMed
  6. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  7. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  8. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  9. Ivasko SM, et al. 2023. Front Immunol. 13:1023206. PubMed
  10. Elliot TAE, et al. 2022. Discov Immunol. 1:kyac009. PubMed
  11. Gon Y, et al. 2023. PLoS One. 18:e0279389. PubMed
  12. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  13. Zheng X, et al. 2019. PLoS Pathog. 15:e1008036. PubMed
  14. He Y, et al. 2023. Biomolecules. 13:. PubMed
  15. Song Y, et al. 2020. Front Immunol. 11:558143. PubMed
  16. van Vloten JP, et al. 2022. J Immunother Cancer. 10:. PubMed
  17. Cordero-Reyes A, et al. 2016. J Am Heart Assoc. 5: 002484. PubMed
  18. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  19. Buxadé M, et al. 2018. J Exp Med. 215:2901. PubMed
  20. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  21. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  22. Castellanos CA, et al. 2021. Sci Immunol. 6:eabh0707. PubMed
  23. Liu Q, et al. 2021. Cell Death Dis. 12:240. PubMed
  24. de Mingo Pulido , et al. 2021. Immunity. 54(6):1154-1167.e7. PubMed
  25. Byun JK, et al. 2020. Molecular Cell. 80(4):592-606.e8. PubMed
  26. Burrack AL, et al. 2019. Cell Rep. 28:2140. PubMed
  27. Chen J et al. 2018. Cell reports. 25(12):3393-3404 . PubMed
  28. Álvaro de Mingo Pulido et al. 2018. Cancer cell. 33(1):60-74 . PubMed
  29. Hasezaki T, et al. 2020. Sci Rep. 10:6969. PubMed
  30. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  31. Luff DH, et al. 2021. Front Immunol. 631271:12. PubMed
  32. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  33. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  34. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  35. Bhattacharjee P, et al. 2018. Sci Rep. 13:e0199785. PubMed
  36. Pereira JL, et al. 2021. Transl Oncol. 14:101125. PubMed
  37. Zirngibl F, et al. 2021. J Immunother Cancer. 9:. PubMed
  38. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  39. Park D, et al. 2020. Cancer Res. 80:4172. PubMed
  40. Mandrup OA, et al. 2021. Commun Biol. 310:4. PubMed
  41. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  42. Brummer G, et al. 2020. Oncogene. 39:2275. PubMed
  43. Leonard JD et al. 2017. Immunity. 47(1):107-117 . PubMed
  44. Uhde A, et al. 2016. PLoS One. 11: 0161883. PubMed
  45. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  46. Baier FA, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:745. PubMed
  47. Fontinha D, et al. 2015. PLoS One. 10: 0142540. PubMed
  48. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  49. Stanford S, et al. 2012. Proc Natl Acad Sci U S A. 109:13972. PubMed
  50. Haile S, et al. 2014. Cancer Immunol Res. 2:610. PubMed
  51. White C, et al. 2015. J Immunol. 194:697. PubMed
  52. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  53. Li C, et al. 2020. Immunity. 52(1):201-202. PubMed
  54. Kang X, et al. 2022. J Immunol Res. 2022:8118577. PubMed
  55. Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed
  56. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  57. Lim S, et al. 2016. PLoS One. 11: 0155689. PubMed
  58. XS R, et al. 2015. Diabetes. 64 90. PubMed
  59. Moore MJ et al. 2018. eLife. 7 pii: e33057. PubMed
  60. Ma K, et al. 2022. iScience. 25:104347. PubMed
  61. Tao F, et al. 2013. Biochem Pharmacol. 85:798. PubMed
  62. Zhang W, et al. 2019. Mar Drugs. 0.845138889. PubMed
  63. Kretschmer L, et al. 2020. Nat Commun. 0.536805556. PubMed
  64. Riva A, et al. 2017. PLoS One.. 10.1371/journal.pone.0181964. PubMed
  65. Wang L, et al. 2021. Sci Adv. 7:eabj4796. PubMed
  66. Jing Y, et al. 2021. Front Immunol. 12:651860. PubMed
  67. Martina M, et al. 2016. J Am Soc Nephrol. 27: 1113-1123. PubMed
  68. Kiss M, et al. 2020. Cancer Immunol Res. 9:309. PubMed
  69. Niven J, et al. 2019. Cell Rep. 28:21. PubMed
  70. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  71. Rui J, et al. 2021. Nat Commun. 12:5074. PubMed
  72. Song TY, et al. 2021. Nat Commun. 12:7003. PubMed
  73. Bommareddy PK, et al. 2019. J Biol Methods. 6:2. PubMed
  74. Skirecki T, et al. 2020. JCI Insight. 5:. PubMed
  75. Klezovich-Bénard M, et al. 2012. PLoS One. 8:e1002481. PubMed
  76. Gardner A, et al. 2022. J Immunother Cancer. 10:. PubMed
  77. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  78. Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed
  79. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
  80. Han J, et al. 2015. Cancer Res . 75: 5273 - 5282. PubMed
  81. Kuhn NF et al. 2019. Cancer cell. 35(3):473-488 . PubMed
  82. Behr FM, et al. 2021. Eur J Immunol. 51:151. PubMed
  83. Jebbawi F, et al. 2021. Parasite Immunol. 43:e12834. PubMed
  84. Parga-Vidal L, et al. 2022. Eur J Immunol. 52:1095. PubMed
  85. Yang J, et al. 2022. Mol Ther Nucleic Acids. 30:184. PubMed
  86. Yu Z, et al. 2022. Biomater Sci. 11:263. PubMed
  87. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  88. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  89. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  90. Ivasko SM, et al. 2023. Front Immunol. 13:1023206. PubMed
  91. Elliot TAE, et al. 2022. Discov Immunol. 1:kyac009. PubMed
  92. Gon Y, et al. 2023. PLoS One. 18:e0279389. PubMed
  93. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  94. Zheng X, et al. 2019. PLoS Pathog. 15:e1008036. PubMed
  95. He Y, et al. 2023. Biomolecules. 13:. PubMed
  96. Song Y, et al. 2020. Front Immunol. 11:558143. PubMed
  97. van Vloten JP, et al. 2022. J Immunother Cancer. 10:. PubMed
  98. Cordero-Reyes A, et al. 2016. J Am Heart Assoc. 5: 002484. PubMed
  99. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  100. Buxadé M, et al. 2018. J Exp Med. 215:2901. PubMed
  101. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  102. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  103. Castellanos CA, et al. 2021. Sci Immunol. 6:eabh0707. PubMed
  104. Liu Q, et al. 2021. Cell Death Dis. 12:240. PubMed
  105. de Mingo Pulido , et al. 2021. Immunity. 54(6):1154-1167.e7. PubMed
  106. Byun JK, et al. 2020. Molecular Cell. 80(4):592-606.e8. PubMed
  107. Burrack AL, et al. 2019. Cell Rep. 28:2140. PubMed
  108. Chen J et al. 2018. Cell reports. 25(12):3393-3404 . PubMed
  109. Álvaro de Mingo Pulido et al. 2018. Cancer cell. 33(1):60-74 . PubMed
  110. Hasezaki T, et al. 2020. Sci Rep. 10:6969. PubMed
  111. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  112. Luff DH, et al. 2021. Front Immunol. 631271:12. PubMed
  113. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  114. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  115. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  116. Bhattacharjee P, et al. 2018. Sci Rep. 13:e0199785. PubMed
  117. Pereira JL, et al. 2021. Transl Oncol. 14:101125. PubMed
  118. Zirngibl F, et al. 2021. J Immunother Cancer. 9:. PubMed
  119. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  120. Park D, et al. 2020. Cancer Res. 80:4172. PubMed
  121. Mandrup OA, et al. 2021. Commun Biol. 310:4. PubMed
  122. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  123. Brummer G, et al. 2020. Oncogene. 39:2275. PubMed
  124. Leonard JD et al. 2017. Immunity. 47(1):107-117 . PubMed
  125. Uhde A, et al. 2016. PLoS One. 11: 0161883. PubMed
  126. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  127. Baier FA, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:745. PubMed
  128. Fontinha D, et al. 2015. PLoS One. 10: 0142540. PubMed
  129. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  130. Stanford S, et al. 2012. Proc Natl Acad Sci U S A. 109:13972. PubMed
  131. Haile S, et al. 2014. Cancer Immunol Res. 2:610. PubMed
  132. White C, et al. 2015. J Immunol. 194:697. PubMed
  133. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  134. Li C, et al. 2020. Immunity. 52(1):201-202. PubMed
  135. Kang X, et al. 2022. J Immunol Res. 2022:8118577. PubMed
  136. Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed
  137. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  138. Lim S, et al. 2016. PLoS One. 11: 0155689. PubMed
  139. XS R, et al. 2015. Diabetes. 64 90. PubMed
  140. Moore MJ et al. 2018. eLife. 7 pii: e33057. PubMed
  141. Ma K, et al. 2022. iScience. 25:104347. PubMed
  142. Tao F, et al. 2013. Biochem Pharmacol. 85:798. PubMed
  143. Zhang W, et al. 2019. Mar Drugs. 0.845138889. PubMed
  144. Kretschmer L, et al. 2020. Nat Commun. 0.536805556. PubMed
  145. Riva A, et al. 2017. PLoS One.. 10.1371/journal.pone.0181964. PubMed
  146. Wang L, et al. 2021. Sci Adv. 7:eabj4796. PubMed
  147. Jing Y, et al. 2021. Front Immunol. 12:651860. PubMed
  148. Martina M, et al. 2016. J Am Soc Nephrol. 27: 1113-1123. PubMed
  149. Kiss M, et al. 2020. Cancer Immunol Res. 9:309. PubMed
  150. Niven J, et al. 2019. Cell Rep. 28:21. PubMed
  151. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  152. Rui J, et al. 2021. Nat Commun. 12:5074. PubMed
  153. Song TY, et al. 2021. Nat Commun. 12:7003. PubMed
  154. Bommareddy PK, et al. 2019. J Biol Methods. 6:2. PubMed
  155. Skirecki T, et al. 2020. JCI Insight. 5:. PubMed
  156. Klezovich-Bénard M, et al. 2012. PLoS One. 8:e1002481. PubMed
  157. Gardner A, et al. 2022. J Immunother Cancer. 10:. PubMed
  158. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  159. Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed
  160. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
  161. Han J, et al. 2015. Cancer Res . 75: 5273 - 5282. PubMed
  162. Kuhn NF et al. 2019. Cancer cell. 35(3):473-488 . PubMed
RRID
AB_313109 (BioLegend Cat. No. 104506)
AB_313108 (BioLegend Cat. No. 104505)

Antigen Details

Structure
C-type lectin, 27/33 kD
Distribution

Activated T cells and B cells, NK cells, granulocytes, thymocytes, platelets

Function
Lymphocyte activation
Cell Type
B cells, Granulocytes, NK cells, Platelets, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Testi R, et al. 1994. Immunol. Today 15:479.
3. Moretta A, et al. 1991. J. Exp. Med. 174:1393.
4. Yokoyama WM, et al. 1988. J. Immunol. 141:369.

Gene ID
12515 View all products for this Gene ID
UniProt
View information about CD69 on UniProt.org

Other Formats

View All CD69 Reagents Request Custom Conjugation
Description Clone Applications
Purified anti-mouse CD69 (Maxpar® Ready) H1.2F3 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD69 H1.2F3 FC
Brilliant Violet 711™ anti-mouse CD69 H1.2F3 FC
Alexa Fluor® 700 anti-mouse CD69 H1.2F3 FC
Brilliant Violet 650™ anti-mouse CD69 H1.2F3 FC
Brilliant Violet 785™ anti-mouse CD69 H1.2F3 FC
TotalSeq™-A0197 anti-mouse CD69 H1.2F3 PG
APC/Fire™ 750 anti-mouse CD69 H1.2F3 FC
TotalSeq™-C0197 anti-mouse CD69 H1.2F3 PG
TotalSeq™-B0197 anti-mouse CD69 H1.2F3 PG
KIRAVIA Blue 520™ anti-mouse CD69 H1.2F3 FC
Spark NIR™ 685 anti-mouse CD69 H1.2F3 FC
Biotin anti-mouse CD69 H1.2F3 FC
FITC anti-mouse CD69 H1.2F3 FC
PE anti-mouse CD69 H1.2F3 FC
PE/Cyanine5 anti-mouse CD69 H1.2F3 FC
Purified anti-mouse CD69 H1.2F3 FC,IHC-F,IP
PE/Cyanine7 anti-mouse CD69 H1.2F3 FC
APC anti-mouse CD69 H1.2F3 FC
Alexa Fluor® 488 anti-mouse CD69 H1.2F3 FC
Alexa Fluor® 647 anti-mouse CD69 H1.2F3 FC
PerCP anti-mouse CD69 H1.2F3 FC
PerCP/Cyanine5.5 anti-mouse CD69 H1.2F3 FC
Pacific Blue™ anti-mouse CD69 H1.2F3 FC
Brilliant Violet 421™ anti-mouse CD69 H1.2F3 FC
APC/Cyanine7 anti-mouse CD69 H1.2F3 FC
Brilliant Violet 605™ anti-mouse CD69 H1.2F3 FC
Brilliant Violet 510™ anti-mouse CD69 H1.2F3 FC
Spark Red™ 718 anti-mouse CD69 H1.2F3 FC
Spark Blue™ 574 anti-mouse CD69 (Flexi-Fluor™) H1.2F3 FC
Spark PLUS B550™ anti-mouse CD69 H1.2F3 FC
Spark PLUS UV395™ anti-mouse CD69 Antibody H1.2F3 FC
Spark YG™ 581 anti-mouse CD69 (Flexi-Fluor™) H1.2F3 FC
Spark YG™ 593 anti-mouse CD69 (Flexi-Fluor™) Antibody H1.2F3 FC
Spark UV™ 387 anti-mouse CD69 (Flexi-Fluor™) H1.2F3 FC
Go To Top Version: 3    Revision Date: 04.18.2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account